Agios Investor Day and First Quarter 2018 Results Read more about Agios Investor Day and First Quarter 2018 Results
Agios to Webcast Investor Day and First Quarter 2018 Financial Results on Friday, May 4, 2018 Read more about Agios to Webcast Investor Day and First Quarter 2018 Financial Results on Friday, May 4, 2018
Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion Read more about Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion
Agios to Present at the Cowen 38th Annual Healthcare Conference Monday, March 12, 2018 Read more about Agios to Present at the Cowen 38th Annual Healthcare Conference Monday, March 12, 2018
FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation Read more about FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation
Agios Reports Fourth Quarter and Full Year 2017 Financial Results Read more about Agios Reports Fourth Quarter and Full Year 2017 Financial Results
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018 Read more about Agios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018
Q4 2017 Agios Pharmaceuticals Inc Earnings Conference Call Read more about Q4 2017 Agios Pharmaceuticals Inc Earnings Conference Call
Agios Pharmaceuticals at Cowen and Company 38th Annual Health Care Conference Read more about Agios Pharmaceuticals at Cowen and Company 38th Annual Health Care Conference
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares Read more about Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares